TY - JOUR
T1 - De novo CD5+ diffuse large B-cell lymphoma, NOS
T2 - clinical characteristics and outcomes in rituximab era
AU - Hu, Bei
AU - Nastoupil, Loretta J.
AU - Loghavi, Sanam
AU - Westin, Jason R.
AU - Thakral, Beenu
AU - Fayad, Luis E.
AU - Hagemeister, Fredrick
AU - Neelapu, Sattva
AU - Samaniego, Felipe
AU - Lee, Hun J.
AU - Wang, Michael L.
AU - Fanale, Michelle
AU - Fowler, Nathan
AU - Oki, Yasuhiro
N1 - Publisher Copyright:
© 2019, © 2019 Informa UK Limited, trading as Taylor & Francis Group.
PY - 2020/1/28
Y1 - 2020/1/28
N2 - CD5+ diffuse large B-cell lymphoma (DLBCL), NOS represents a distinct subset of DLBCL associated with poorer outcomes and extranodal disease. We analyzed characteristics and outcomes for 102 CD5+ DLBCL patients diagnosed between 2001-2016. The majority had poor-risk disease based on R-IPI scores; 80% had extranodal disease at diagnosis. CNS relapse occurred 23% of the time. Median PFS and OS was 18.9 months and 112 months, respectively. Four-year PFS rates were 100%, 53%, and 41% for patients with R-IPI scores of very good, good, and poor, respectively. CD5+ DLBCL represents a subset of patients with poor outcomes despite rituximab and anthracycline-based regimens. There is a need for novel therapies and clinical trials for this high-risk group of patients. Given high rates of CNS relapse, better CNS prophylaxis with frontline therapy requires more study.
AB - CD5+ diffuse large B-cell lymphoma (DLBCL), NOS represents a distinct subset of DLBCL associated with poorer outcomes and extranodal disease. We analyzed characteristics and outcomes for 102 CD5+ DLBCL patients diagnosed between 2001-2016. The majority had poor-risk disease based on R-IPI scores; 80% had extranodal disease at diagnosis. CNS relapse occurred 23% of the time. Median PFS and OS was 18.9 months and 112 months, respectively. Four-year PFS rates were 100%, 53%, and 41% for patients with R-IPI scores of very good, good, and poor, respectively. CD5+ DLBCL represents a subset of patients with poor outcomes despite rituximab and anthracycline-based regimens. There is a need for novel therapies and clinical trials for this high-risk group of patients. Given high rates of CNS relapse, better CNS prophylaxis with frontline therapy requires more study.
KW - CD5+ DLBCL
KW - CNS relapse
KW - extranodal disease
KW - retrospective review
UR - http://www.scopus.com/inward/record.url?scp=85074014791&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85074014791&partnerID=8YFLogxK
U2 - 10.1080/10428194.2019.1663418
DO - 10.1080/10428194.2019.1663418
M3 - Article
C2 - 31533521
AN - SCOPUS:85074014791
SN - 1042-8194
VL - 61
SP - 328
EP - 336
JO - Leukemia and Lymphoma
JF - Leukemia and Lymphoma
IS - 2
ER -